INFECTA
INFECTA
INFECTA is a not-for-profit, full-service clinical research organization dedicated to early-phase clinical research in infectious diseases. We are based at the Leiden Bio Science Park. Building on decades of experience, we have supported the development of innovative therapies and vaccines with a focus on quality, ethics and care.
Founded in 2024, INFECTA emerged from the longstanding collaboration between Leiden University Center for Infectious Diseases and the Centre for Human Drug Research (CHDR). This allows us to leverage nearly four decades of experience in early-phase clinical trials. INFECTA combines regulatory knowledge with operational expertise rooted in academic rigor.
Our approach centers on efficient clinical trials using smart study design, with Controlled Human Infection Models (CHIMs) integrated whenever suitable. This enables us to collect early-phase clinical data on effectiveness, safety, and immune response in a controlled environment, generating results faster and with fewer participants than traditional field trials.
By improving how infectious disease products are evaluated we not only save years of development time and reduce costs, but also work to bring better treatments and vaccines to market more affordably, supporting broader global access to essential interventions.
INFECTA was founded by Prof. Dr. Meta Roestenberg and Dr. Ingrid de Visser-Kamerling, two experienced leaders who share a commitment to advancing global health through infectious disease research.